Autologous Bone Marrow Mononuclear Cell Transplantation for Multiple System Atrophy Type C- a Case Report

Author(s)

Sarita Kalburgi , Alok Sharma , Hemangi Sane , Pooja Kulkarni , Sanket Inamdar , Khushboo Bhagwanani , Nandini Gokulchandran , Prerna Badhe ,

Download Full PDF Pages: 40-45 | Views: 995 | Downloads: 187 | DOI: 10.5281/zenodo.3442068

Volume 6 - January 2017 (01)

Abstract

Multiple system atrophy (MSA) is a neurodegenerative disorder clinically characterized by various combinations of cerebellar, autonomic or pyramidal signs and symptoms and pathologically by cell loss, gliosis in brain and spinal cord structures. Treatments available for MSA are largely palliative. Novel approaches to alter the disease progression are required. Cell therapy has shown promising findings in preclinical studies. Herein we present a case report of 50 years old male patient diagnosed as a case of Multiple System Atrophy type C. His symptoms started at the age of 46 years and the condition was deteriorating inspite of regular treatment. Patient underwent intrathecal autologous bone marrow mononuclear cell transplantation and neurorehabilitation. Six months after transplantation, significant improvements in speech, fine motor activities, balance and ambulation were noted. There were improvements in the cerebellar signs and symptoms and outcome measures of Modified International Co-operative Ataxia Rating scale (34 to 31) and the Brief Ataxia Rating Scale (7 to 6). In view of his improvements second cell transplantation was done after 9 months. The improvements were maintained with no further deterioration for the next 21 months post transplantation. This highlights the potential of combination treatment of cell therapy and neurorehabilitation to alter the disease progression in MSA

Keywords

Autologous bone marrow mononuclear cells (BMMNC); stem cells; cell therapy; multiple system atrophy-C (MSA-C); MICARS; BARS

References

     i.        D J Burn, E Jaros, Multiple system atrophy: cellular and molecular pathology, J Clin Pathol: Mol Pathol 2001;54:419–426.

  1. Wenning GK, Jellinger KA. The role of alpha-synuclein in the pathogenesis of multiple system atrophy. Acta Neuropathol, 2005; 109:129-40. 
  2. Olivier Flabeau, Wassilios G. Meissner and Franc¸ois Tison, Multiple system atrophy: current and future approaches to management Ther Adv Neurol Disord (2010) 3(4) 249_263
  3. Schrag, A., Wenning, G.K., Quinn, N. and Ben-Shlomo, Y. Survival in multiple system atrophy. Mov Disord, 2008; 23: 294_296.
  4. Wenning G.K., Stefanova N. Recent developments in multiple system atrophy. J. Neurol, 2009; 256:1791–1808.
  5. Stemberger S., Jamnig A., Stefanova N., Lepperdinger G., Reindl M., Wenning G.K. Mesenchymal stem cells in a transgenic mouse model of multiple system atrophy: immunomodulation and neuroprotection. Plos ONE, 2011; 6. 
  6. Alok Sharma, Hemangi Sane et al. Cellular transplantation may modulate disease progression in spinocerebellar ataxia- A case report. Indian Journal of Medical Research and Pharmaceutical Sciences, 2014; 1(3).
  7. Alok Sharma, Hemangi Sane et al. Autologous Bone Marrow Mononuclear Cells Intrathecal Transplantation in chronic stroke. Hidawi Publishing Corporation, Stroke research and treatment; 2014.
  8. R. V. Carlson, K. M. Boyd, and D. J. Webb, “The revision of the declaration of Helsinki: past, present and future,” British Journal of Clinical Pharmacology, 2004; 57( 6): 695–713.
  9. Hwan Yoon, Shik Shim et al. Complete Spinal Cord Injury Treatment Using Autologous Bone Marrow Transplantation and Bone Marrow Stimulation with Granulocyte Macrophage-Colony Stimulating Factor: Phase I/II Clinical Trial. Tissue Engineering, 2005; 11 (5-6):913-922.
  10. Felix Geser and Gregor K. Wenning. chapt 20, Multiple System atrophy, Current Clinical Neurology: Atypical Parkinsonian Disorders; 335-360.
  11. Wakabayashi K, Takahashi H. Cellular pathology in multiple system atrophy. Neuropathology 2006;26:338–345.
  12. Windisch M, Wolf HJ, Hutter-Paier B, Wronski R. Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders? Curr Alzheimer Res 2007;4:556–561.
  13. Sharma A, Gokulchandran N. Stem cell therapy in neurological disorders. 1 st edition, India 2010.
  14. D. I. Jung, J. Ha, B. T. Kang et al., “A comparison of autologous and allogenic bone marrow-derived mesenchymal stem cell transplantation in canine spinal cord injury,” Journal of the Neurological Sciences, 2009; 285 (1-2): 67–77.
  15. A Sharma, P Badhe, Administration of Autologous Bone Marrow Stem Cells Intrathecally in Multiple Sclerosis Patients is Safe and Improves their Quality-of-life. Indian Journal of Clinical Practice, 2011, Vol. 21 No. 11;622-25
  16. Stefanova N, Bucke P, Duerr S, Wenning GK (2009) Multiple system atrophy: an update. Lancet Neurol 8: 1172–1178.
  17. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, et al. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290: 985–989.
  18. Jellinger KA (2003) Neuropathological spectrum of synucleinopathies. Mov Disord 18: Suppl 6S2–12
  19. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8: 382–397. 
  20. N. Payne, C. Siatskas, A. Barnard, and C. C. A. Bernard, “prospect of stem cells as multi-faceted purveyors of immune modulation, repair and regeneration in multiple sclerosis,”Current Stem Cell Research and Therapy, 2011; 6 (1): 5.
  21. P. M. Chen, M. L. Yen, K. J. Liu, H. K. Sytwu, and B. L Yen, “Immuno-modulatory properties of human adult and fetal multipotent mesenchymal stem cells,” Journal of Biomedical Sciences, 2011; 18 (49).
  22. M. X. Xiang, A. N. He, J. A. Wang, and C. Gui, “Protective paracrine effect of mesenchymal stem cells on cardiomyocytes,” Journal of Zhejiang University B, 2009; 10 (8): 619–624.
  23. P. R. Crisostomo, M. Wang, T. A. Markel et al., “Stem cell mechanisms and paracrine effects: potential in cardiac surgery,” Shock, vol. 28, no. 4, pp. 375–383, 2007.
  24. Veen M, Jeppesen T, Hauerslev S, Køber L, Krag T, Vissing J, “Endurance training improves fitness and strength in patients with Becker muscular dystrophy.” in Brain, 2008; 131(11):2824-31

Cite this Article: